ClinicalTrials.gg
CompletedNCT04383418Updated Oct 28, 2026

A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Adults

A Phase 3 interventional study of dexmedetomidine hydrochloride nasal spray and dexmedetomidine hydrochloride nasal spray blank preparation in Preoperative Sedation, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

Updated Oct 28, 2026Now CompletedEligibility revised+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
309
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The study is being conducted to evaluate the efficacy and safety of dexmedetomidine hydrochloride nasal spray for preoperative sedation in adults. To explore the reasonable dosage of dexmedetomidine hydrochloride nasal spray for preoperative sedation.

02

Conditions studied

  • Preoperative Sedation
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written .
  2. Scheduled for elective abdominal surgery (excluding hepatic surgery) under general anesthesia, with an expected operative duration of 1-4 hours.
  3. Male or female adults aged between 18 and 65 years,
  4. Meet the weight standard:18.5 kg/m²≤≤30 kg/m²
  5. Conform to the ASA Physical Status Classification:classification I II.

Exclusion criteria

Exclusion Criteria:

  1. Not suitable for nasal spray
  2. Having received general anesthesia within 28 days prior to randomization
  3. Subjects with a history of myocardial infarction or unstable angina pectoris
  4. Subjects with heart rate\<60beats/min at screening, or a history of severe arrhythmia such as second degree type II or higher atrioventricular block, or a history of cardiac insufficiency
  5. Subjects with a history of ischemic stroke or
  6. Subjects with poor blood pressure control after medication
  7. Subjects with abnormal clotting function
  8. Subjects with a history of mental illness and a history of cognitive impairment epilepsy
  9. Subjects with a history or possibility of a difficult airway
  10. Subject with a history of substance abuse and drug abuse
  11. Adrenoceptor agonists or antagonists were used before randomization:Phase 1: Subjects who have received α2-adrenergic receptor agonists or antagonists within 14 days prior to randomization.

    Phase 2: Subjects who have received selective α2-adrenergic receptor agonists or antagonists within 14 days prior to randomization;

  12. Uncontrolled hepatic or renal dysfunction
  13. Thyroid dysfunction
  14. Allergic to a drug ingredient or component
  15. Pregnant or nursing women
  16. No during the specified period of time
  17. Participated in clinical trials of other drugs (received experimental drugs)
  18. The investigators determined that other conditions were inappropriate for participation in this clinical trial
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
309 participants (actual)

Study arms

  • Experimental
    High dose group

    In this group, subjects received a higher dose of dexmedetomidine hydrochloride nasal spray.

    Drug: dexmedetomidine hydrochloride nasal spray

  • Experimental
    Low dose group

    In this group, subjects received a lower dose of dexmedetomidine hydrochloride nasal spray

    Drug: dexmedetomidine hydrochloride nasal spray

  • Placebo comparator
    Placebo group

    In the placebo group, subjects received dexmedetomidine hydrochloride nasal spray blank preparation.

    Drug: dexmedetomidine hydrochloride nasal spray blank preparation

Interventions

  • dexmedetomidine hydrochloride nasal spray

  • Drugdexmedetomidine hydrochloride nasal spray blank preparation

    dexmedetomidine hydrochloride nasal spray blank preparation

06

What researchers measure

Primary outcomes

  1. Proportion of subjects who attained a Ramsay Sedation Score ≥3 at least once within 45 minutes

    Evaluated with Ramsay sedation scale Score Response 1. Anxious or restless or both 2. Cooperative, orientated and tranquil 3. Responding to commands 4. Brisk response to stimulus 5. Sluggish response to stimulus 6. No response to stimulus

    Time frame: 0 minutes to 45 minutes after administration

Secondary outcomes

  1. Stage I : Propofol infusion rate (mg/kg/h) from the initiation of anesthetic induction until the first time BIS value ≤60 is achieved

    Time frame: The BIS value reaches 60 for the first time during intraoperative

  2. Stage I : Propofol infusion rate (mg/kg/h) during general anesthesia

    Time frame: From the beginning of anesthesia to the end of surgical operation up to 4 hours

  3. Stage I : Opioid analgesic infusion rate (μg/kg/min) from the initiation of anesthetic induction until the first time BIS value ≤60 is achieved

    Time frame: The BIS value reaches 60 for the first time during intraoperative

  4. Stage I : Opioid analgesic infusion rate (μg/kg/min) during general anesthesia

    Time frame: From the beginning of anesthesia to the end of surgical operation up to 4 hours

  5. Stage I : The BIS value at the time when Ramsay Sedation Score first reaches ≥3 after study drug administration

    Time frame: The Ramsay Sedation Score ≥3 for the first time during intraoperative

  6. Stage I : Anesthesiologist satisfaction rating

    The anesthesiologist satisfaction rating is a scale of 0 to 10, satisfaction defined as a scale of 10, dissatisfaction defined as a scale of 0.

    Time frame: At the end of surgery when the patient recovers from anesthesia

  7. Stage I : Subjects' satisfaction rating

    The subjects' satisfaction rating is a scale of 0 to 10, satisfaction defined as a scale of 10, dissatisfaction defined as a scale of 0.

    Time frame: From the end of surgical operation up to 24 hours

  8. Stage II: Total dose of propofol (mg/kg) administered from anesthesia induction to achieve a BIS value ≤60

    Time frame: The BIS value reaches 60 for the first time during intraoperative

  9. Stage II: Changes in BIS value from baseline at 15, 30, and 45 minutes after study drug administration.

    Time frame: 15, 30, and 45 minutes after study drug administration

  10. Stage II: Anesthesiologist satisfaction rating

    The anesthesiologist satisfaction rating is a scale of 0 to 10, satisfaction defined as a scale of 10, dissatisfaction defined as a scale of 0

    Time frame: At the end of surgery when the patient recovers from anesthesia

  11. Stage II: Time from the start of study drug administration to the first achievement of Ramsay Sedation Score ≥3

    Time frame: From administration to the beginning of anesthesia

  12. Safety Endpoints ( Stage I / Stage II) : Incidence and severity of adverse events

    Time frame: Within 2 days after study drug administration

07

Study locations

1 site
  • Zhongshan Hospital Fudan University
    Shanghai, 200032, China
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2020 to primary completion in Jun 2021, 12 months.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2021 → Jun 2021, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2020
First posted
May 12, 2020
StartActual
May 31, 2020
Primary completionActual
Jun 2, 2021
CompletionActual
Jun 2, 2021was Sep 2021
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 23, 2026
Sites
1 site added, 1 site removed
Show site
  • Zhongshan Hospital Fudan University · Shanghai, China
Show 1 removed
  • Zhongshan Hospital Fudan University · Shanghai, China
Oct 23, 2026
Study completion
Sep 10, 2021→Jun 2, 2021 (actual)
Oct 23, 2026
Enrollment
201→309
Oct 23, 2026
Eligibility
Criteria revised in 2 updates
What changed on Oct 23, 2026
Inclusion criteria
  • RemovedSubjects requiring elective general anesthesia surgery
  • RemovedMale or female
  • RemovedMeet the weight standard
  • RemovedConform to the ASA Physical Status Classification
  • AddedScheduled for elective abdominal surgery (excluding hepatic surgery) under general anesthesia, with an expected operative duration of 1-4 hours 3. Male or female adults aged between 18 and 65 years,
  • Added4. Meet the weight standard:18.5 kg/m²≤BMI≤30 kg/m² 5. Conform to the ASA Physical Status Classification:classification I II.
Exclusion criteria
  • ChangedBefore Subjects who had received general anesthesiaNow Having received general anesthesia within 28 days prior to randomization
  • ChangedBefore Subjects with atrioventricular block or cardiac insufficiencyNow Subjects with heart rate<60beats/min at screening, or a history of severe arrhythmia such as second degree type II or higher atrioventricular block, or a history of cardiac insufficiency
  • RemovedAdrenoceptor agonists or antagonists were used before randomization
  • RemovedAbnormal values in the laboratory
  • AddedAdrenoceptor agonists or antagonists were used before randomization:Phase 1: Subjects who have received α2-adrenergic receptor agonists or antagonists within 14 days prior to randomization.
  • AddedPhase 2: Subjects who have received selective α2-adrenergic receptor agonists or antagonists within 14 days prior to randomization;
  • AddedUncontrolled hepatic or renal dysfunction
  • EditedThe inestigatorsinvestigators determined that other conditions were inappropriate for participation in this clinical trial
What changed on Oct 28, 2026
Inclusion criteria
  • EditedScheduled for elective abdominal surgery (excluding hepatic surgery) under general anesthesia, with an expected operative duration of 1-4 hours 3. Male or female adults aged between 18 and 65 years,
  • AddedMale or female adults aged between 18 and 65 years,
  • Edited4. Meet the weight standard:18.5 kg/m²≤BMI≤30 kg/m² 5. Conform to the ASA Physical Status Classification:classification I II.
  • AddedConform to the ASA Physical Status Classification:classification I II.
across 2 updates, Oct 23, 2026 – Oct 28, 2026
Interventions
Changed dexmedetomidine nasal spray→dexmedetomidine hydrochloride nasal spray
Oct 23, 2026
Primary outcomes
Revised in 2 updates
What changed on Oct 23, 2026
  • EditedProportion of subjects who meet theattained a Ramsay sedation score of Sedation Score ≥3 at least once within 45 minutesTime frame: 0 minute to 45 minutes after administration → 0 minutes to 45 minutes after administration
  • AddedSafety Endpoints : Incidence and severity of adverse eventsTime frame: Within 2 days after study drug administration
What changed on Oct 28, 2026
  • RemovedSafety Endpoints : Incidence and severity of adverse eventsTime frame: Within 2 days after study drug administration
across 2 updates, Oct 23, 2026 – Oct 28, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 23, 2026
  • EditedStage I : The BIS value forat the time when Ramsay sedation score of 3 for theSedation Score first timereaches ≥3 after study drug administrationTime frame: The Ramsay sedation score of 3 for the first time during intraoperative → The Ramsay Sedation Score ≥3 for the first time during intraoperative
  • EditedStage I : Anesthesiologist satisfaction ratingTime frame: At the end of surgery when the patient recovers from anesthesia
  • EditedStage I : Subjects' satisfaction ratingTime frame: From the end of surgical operation up to 24 hours
  • AddedStage I : Propofol infusion rate (mg/kg/h) from the initiation of anesthetic induction until the first time BIS value ≤60 is achievedTime frame: The BIS value reaches 60 for the first time during intraoperative
  • AddedStage I : Propofol infusion rate (mg/kg/h) during general anesthesiaTime frame: From the beginning of anesthesia to the end of surgical operation up to 4 hours
  • AddedStage I : Opioid analgesic infusion rate (μg/kg/min) from the initiation of anesthetic induction until the first time BIS value ≤60 is achievedTime frame: The BIS value reaches 60 for the first time during intraoperative
  • AddedStage I : Opioid analgesic infusion rate (μg/kg/min) during general anesthesiaTime frame: From the beginning of anesthesia to the end of surgical operation up to 4 hours
  • AddedStage II: Total dose of propofol (mg/kg) administered from anesthesia induction to achieve a BIS value ≤60Time frame: The BIS value reaches 60 for the first time during intraoperative
  • AddedStage II: Changes in BIS value from baseline at 15, 30, and 45 minutes after study drug administration.Time frame: 15, 30, and 45 minutes after study drug administration
  • AddedStage II: Anesthesiologist satisfaction ratingTime frame: At the end of surgery when the patient recovers from anesthesia
  • AddedStage II: Time from the start of study drug administration to the first achievement of Ramsay Sedation Score ≥3Time frame: From administration to the beginning of anesthesia
  • RemovedTotal consumption of propofol during bispectral index reaches 60 for the first timeTime frame: The bispectral index reaches 60 for the first time during intraoperative
  • RemovedTotal consumption of propofol during general anesthesiaTime frame: From the beginning of anesthesia to the end of surgical operation up to 4 hours
  • RemovedTotal consumption of opioid analgesic during bispectral index reaches 60 for the first timeTime frame: The bispectral index reaches 60 for the first time during intraoperative
  • RemovedTotal consumption of opioid analgesic during general anesthesiaTime frame: From the beginning of anesthesia to the end of surgical operation up to 4 hours
What changed on Oct 28, 2026
  • AddedSafety Endpoints ( Stage I / Stage II) : Incidence and severity of adverse eventsTime frame: Within 2 days after study drug administration
across 2 updates, Oct 23, 2026 – Oct 28, 2026
Design
Removed Phase 2
Oct 23, 2026
Show all 2 updates
  1. Oct 28, 2026
    Eligibility 2 inclusion criteria edited, 2 added
    What changed in the criteria
    Inclusion criteria
    • EditedScheduled for elective abdominal surgery (excluding hepatic surgery) under general anesthesia, with an expected operative duration of 1-4 hours 3. Male or female adults aged between 18 and 65 years,
    • AddedMale or female adults aged between 18 and 65 years,
    • Edited4. Meet the weight standard:18.5 kg/m²≤BMI≤30 kg/m² 5. Conform to the ASA Physical Status Classification:classification I II.
    • AddedConform to the ASA Physical Status Classification:classification I II.
    Primary outcomes 1 removed
    What changed in the outcomes
    • RemovedSafety Endpoints : Incidence and severity of adverse eventsTime frame: Within 2 days after study drug administration
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedSafety Endpoints ( Stage I / Stage II) : Incidence and severity of adverse eventsTime frame: Within 2 days after study drug administration
  2. Oct 23, 2026
    Status unknown→Completed
    1 site added, 1 site removed
    Show site
    • Zhongshan Hospital Fudan University · Shanghai, China
    Show 1 removed
    • Zhongshan Hospital Fudan University · Shanghai, China
    Study completion Sep 10, 2021→Jun 2, 2021 (now actual)
    Enrollment 201→309
    Eligibility 2 inclusion criteria added, 4 removed; 3 exclusion criteria edited, 3 added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedSubjects requiring elective general anesthesia surgery
    • RemovedMale or female
    • RemovedMeet the weight standard
    • RemovedConform to the ASA Physical Status Classification
    • AddedScheduled for elective abdominal surgery (excluding hepatic surgery) under general anesthesia, with an expected operative duration of 1-4 hours 3. Male or female adults aged between 18 and 65 years,
    • Added4. Meet the weight standard:18.5 kg/m²≤BMI≤30 kg/m² 5. Conform to the ASA Physical Status Classification:classification I II.
    Exclusion criteria
    • ChangedBefore Subjects who had received general anesthesiaNow Having received general anesthesia within 28 days prior to randomization
    • ChangedBefore Subjects with atrioventricular block or cardiac insufficiencyNow Subjects with heart rate<60beats/min at screening, or a history of severe arrhythmia such as second degree type II or higher atrioventricular block, or a history of cardiac insufficiency
    • RemovedAdrenoceptor agonists or antagonists were used before randomization
    • RemovedAbnormal values in the laboratory
    • AddedAdrenoceptor agonists or antagonists were used before randomization:Phase 1: Subjects who have received α2-adrenergic receptor agonists or antagonists within 14 days prior to randomization.
    • AddedPhase 2: Subjects who have received selective α2-adrenergic receptor agonists or antagonists within 14 days prior to randomization;
    • AddedUncontrolled hepatic or renal dysfunction
    • EditedThe inestigatorsinvestigators determined that other conditions were inappropriate for participation in this clinical trial
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedProportion of subjects who meet theattained a Ramsay sedation score of Sedation Score ≥3 at least once within 45 minutesTime frame: 0 minute to 45 minutes after administration → 0 minutes to 45 minutes after administration
    • AddedSafety Endpoints : Incidence and severity of adverse eventsTime frame: Within 2 days after study drug administration
    Secondary outcomes 3 edited, 8 added, 4 removed
    What changed in the outcomes
    • EditedStage I : The BIS value forat the time when Ramsay sedation score of 3 for theSedation Score first timereaches ≥3 after study drug administrationTime frame: The Ramsay sedation score of 3 for the first time during intraoperative → The Ramsay Sedation Score ≥3 for the first time during intraoperative
    • EditedStage I : Anesthesiologist satisfaction ratingTime frame: At the end of surgery when the patient recovers from anesthesia
    • EditedStage I : Subjects' satisfaction ratingTime frame: From the end of surgical operation up to 24 hours
    • AddedStage I : Propofol infusion rate (mg/kg/h) from the initiation of anesthetic induction until the first time BIS value ≤60 is achievedTime frame: The BIS value reaches 60 for the first time during intraoperative
    • AddedStage I : Propofol infusion rate (mg/kg/h) during general anesthesiaTime frame: From the beginning of anesthesia to the end of surgical operation up to 4 hours
    • AddedStage I : Opioid analgesic infusion rate (μg/kg/min) from the initiation of anesthetic induction until the first time BIS value ≤60 is achievedTime frame: The BIS value reaches 60 for the first time during intraoperative
    • AddedStage I : Opioid analgesic infusion rate (μg/kg/min) during general anesthesiaTime frame: From the beginning of anesthesia to the end of surgical operation up to 4 hours
    • AddedStage II: Total dose of propofol (mg/kg) administered from anesthesia induction to achieve a BIS value ≤60Time frame: The BIS value reaches 60 for the first time during intraoperative
    • AddedStage II: Changes in BIS value from baseline at 15, 30, and 45 minutes after study drug administration.Time frame: 15, 30, and 45 minutes after study drug administration
    • AddedStage II: Anesthesiologist satisfaction ratingTime frame: At the end of surgery when the patient recovers from anesthesia
    • AddedStage II: Time from the start of study drug administration to the first achievement of Ramsay Sedation Score ≥3Time frame: From administration to the beginning of anesthesia
    • RemovedTotal consumption of propofol during bispectral index reaches 60 for the first timeTime frame: The bispectral index reaches 60 for the first time during intraoperative
    • RemovedTotal consumption of propofol during general anesthesiaTime frame: From the beginning of anesthesia to the end of surgical operation up to 4 hours
    • RemovedTotal consumption of opioid analgesic during bispectral index reaches 60 for the first timeTime frame: The bispectral index reaches 60 for the first time during intraoperative
    • RemovedTotal consumption of opioid analgesic during general anesthesiaTime frame: From the beginning of anesthesia to the end of surgical operation up to 4 hours
    Interventions Changed dexmedetomidine nasal spray→dexmedetomidine hydrochloride nasal spray
    Design Removed Phase 2
    + 3 other changes: verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04383418
Responsible party
Sponsor
First posted
May 12, 2020
Start date
May 31, 2020
Primary completion
Jun 2, 2021
Completion
Jun 2, 2021
Last update
Oct 28, 2026

Study contacts

Changhong Miao, PhD
principal investigator · Zhongshan Hospital, Fudan University, Shanghai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion